Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis by Veldink, J.H. et al.
doi:10.1136/jnnp.2005.083378 
 published online 28 Apr 2006; J. Neurol. Neurosurg. Psychiatry
  
Wokke and Leonard H. van den Berg 
Annemarie Koster, Jeanne H.M. de Vries, Jolanda van der Luyt, John H.J. 
Jan H Veldink, Sandra Kalmijn, Geert-Jan Groeneveld, Wendy Wunderink,
  
 E reduce the risk of developing ALS
Intake of Polyunsaturated fatty acids and vitamin
 http://jnnp.bmj.com/cgi/content/abstract/jnnp.2005.083378v2
Updated information and services can be found at: 
 These include:
Rapid responses
 http://jnnp.bmj.com/cgi/eletter-submit/jnnp.2005.083378v2
You can respond to this article at: 
  
 http://jnnp.bmj.com#responses
free at: 
2 rapid responses have been posted to this article, which you can access for
 service
Email alerting
the top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at
 Notes   
initial publication. 
Citations to Online First articles must include the digital object identifier (DOIs) and date of
citable and establish publication priority; they are indexed by PubMed from initial publication. 
versions may be posted when available prior to final publication). Online First articles are
accepted for publication but have not yet appeared in the paper journal (edited, typeset 
 contains unedited articles in manuscript form that have been peer reviewed andOnline First
 http://www.bmjjournals.com/cgi/reprintform
To order reprints of this article go to: 
 http://www.bmjjournals.com/subscriptions/
 go to: Journal of Neurology, Neurosurgery, and PsychiatryTo subscribe to 
 on 16 February 2007 jnnp.bmj.comDownloaded from 
PAPER
Intake of polyunsaturated fatty acids and vitamin E reduces
the risk of developing amyotrophic lateral sclerosis
J H Veldink, S Kalmijn, G-J Groeneveld, W Wunderink, A Koster, J H M de Vries, J van der Luyt,
J H J Wokke, L H Van den Berg
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Jan H Veldink, Department
of Neurology, University
Medical Center Utrecht, G.
03.228, PO Box 85500,
3508 GA Utrecht, The
Netherlands; j.h.veldink@
umcutrecht.nl
Received1November2005
Revised version received
28 February 2006
Accepted 14 March 2006
. . . . . . . . . . . . . . . . . . . . . . .
J Neurol Neurosurg Psychiatry 2006;000:1–6. doi: 10.1136/jnnp.2005.083378
Background: To assess whether the premorbid dietary intake of fatty acids, cholesterol, glutamate or
antioxidants was associated with the risk of developing amyotrophic lateral sclerosis (ALS).
Methods: Patients referred to our clinic during 2001–2002, who had definite, probable or possible ALS
according to El Escorial criteria, without a familial history of ALS, were asked to participate in a case–
control study (132 patients and 220 healthy controls). A food-frequency questionnaire was used to assess
dietary intake for the nutrients of interest. Multivariate logistic regression analysis was performed with
adjustment for confounding factors (sex, age, level of education, energy intake, body mass index and
smoking).
Results: A high intake of polyunsaturated fatty acid (PUFA) and vitamin E was significantly associated with
a reduced risk of developing ALS (PUFA: odds ratio (OR) = 0.4, 95% confidence interval (CI) = 0.2 to 0.7,
p = 0.001; vitamin E: OR=0.4, 95% CI = 0.2 to 0.7, p = 0.001). PUFA and vitamin E appeared to act
synergistically, because in a combined analysis the trend OR for vitamin E was further reduced from 0.67
to 0.37 (p = 0.02), and that for PUFA from 0.60 to 0.26 (p = 0.005), with a significant interaction term
(p = 0.03). The intake of flavonols, lycopene, vitamin C, vitamin B2, glutamate, calcium or phytoestrogens
was not associated with the risk of developing ALS.
Conclusion: A high intake of PUFAs and vitamin E is associated with a 50–60% decreased risk of
developing ALS, and these nutrients appear to act synergistically.
S
poradic amyotrophic lateral sclerosis (ALS) probably
develops through the combined effects of several
modifying genes and environmental factors.1 Despite
several studies that investigated environmental exposures in
relation to ALS, age, gender and smoking are the only
established risk factors.2 Several, not mutually exclusive,
pathological processes may contribute to motor neurone
death in ALS in a so-called convergence model,3 including
oxidative stress, mitochondrial dysfunction, protein misfold-
ing, axonal strangulation, apoptosis, inflammation, gluta-
mate excitotoxicity and defects in neurotrophin biology.
Nutrients are factors that could influence these processes and
thereby the risk of developing ALS or its clinical expression.
ALS was previously found to be positively associated with
intake of glutamate,4 fat,4 fish5 and milk,6 7 and inversely
associated with intake of lycopene,8 dietary fibre,4 bread and
pasta.9 Two other studies, however, failed to establish the
relationship with milk.10 11 Several of these studies included
only small samples of patients (,25),5 6 9 or investigated
nutrition as one of many environmental factors, thus
increasing the likelihood of chance findings.5–7 9–11
Furthermore, most studies did not account for the possible
influence of clinical onset preceding the diagnosis5–11 or
adjust for possible confounders including total energy intake,
body mass index (BMI), sex, smoking and education.5–7 9–11
One study found an association between intake of total fat
and ALS, although this was not hypothesised beforehand.4
This finding is of interest considering the observed associa-
tions of intake of saturated and unsaturated fatty acids and
cholesterol with other neurodegenerative diseases.12 In this
case–control study, therefore, we examined the possible
association between premorbid dietary intake of fatty acids,
cholesterol, glutamate, phytoestrogens, calcium and anti-
oxidants and the risk of developing ALS, adjusting for
confounding factors.
PATIENTS AND METHODS
Patients
The University Hospitals in Amsterdam and Utrecht are
national referral centres for ALS in The Netherlands. All
patients included in this study were incident cases, who
visited our clinics for diagnostic purposes during the 1-year
period between 2001 and 2002. Every patient who visited our
clinic during this period and who had definite, probable or
possible ALS according to El Escorial criteria,13 without a
familial history of ALS, was asked to participate in the study.
Because patients with suspected ALS may present a collection
of other syndromes, only patients with both upper and lower
motor neurone involvement were included.14 Accordingly, a
total of 184 patients were identified and were sent a
questionnaire, 132 (72%) of which were returned. Duration
of disease, defined as the interval between onset of muscle
weakness and death from any cause, tracheostomy or
persistent assisted ventilation, was used for the survival
analysis. The survival status of patients was monitored until
May 2004. The 52 patients who did not return the
questionnaire did not differ significantly from the 132
patients who did, with respect to sex, age at onset, duration
of disease and type of onset.
Controls
Patients were sent three identical questionnaires. One
questionnaire was to be completed by the patient and the
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other two by controls. Every patient was asked to approach
two persons who fulfilled the following criteria:
N should not be their spouse or partner
N should preferably not differ from them in age by more
than 5 years
N should preferably be of the same sex.
Of 264 controls, 220 (83%) returned their questionnaires.
All questionnaires remained anonymous, and all data were
entered in a blinded fashion.
Questionnaire
The questionnaire was divided into two sections: the first
section contained questions on age, sex, level of education,
smoking and anthropometrical characteristics; the second
section consisted of questions on food frequency. Patients
were asked to recall their dietary habits during the period
1 year before the onset of muscle weakness or bulbar signs,
to avoid a possible influence of subclinical disease on the
factors of interest. Patients had to disclose this reference year
to their controls, who had to report their dietary habits in the
same reference year.
The food-frequency questionnaire had 104 questions that
were validated for the intake of total energy, total fat, fatty
acids and cholesterol.15 The questionnaire was validated
against linoleic acid concentrations in erythrocytes and
adipose tissue as biomarkers of intake. These biomarkers
were shown to be representative of long-term intake of fatty
acids, as the half-life of linoleic acid in adipose tissue is
approximately 680 days. The results of the questionnaire,
therefore, are representative of a longer period of food intake.
Considering the hypotheses of this study, the questionnaire
was extended with questions on the dietary intake of
glutamate, flavonols, lycopene, vitamin B2, vitamin C,
vitamin E, calcium and phytoestrogens. Therefore, 37 items
were added according to a systematic procedure. Food items
for the original questionnaire were chosen on the basis of
data from the Dutch National Food Consumption Survey of
1992.16 Data regarding vitamin C were also available from this
survey, but other sources were used for the remaining
nutrients: the national survey of 1987–1988;17 national
reports by TNO Nutrition and Food Research and the Dutch
Food Composition Tables (Nevo) for calcium, vitamin B2 and
vitamin E; publications on flavonoids;18 19 the US Department
of Agriculture table for phytoestrogens (isoflavones);20 pub-
lications on glutamate and monosodium glutamate;21–25 and
the US Department of Agriculture table for lycopene.20 The 37
items that were added to the questionnaire on the basis of
these sources accounted for at least 95% of the intake of a
specific factor.
If questionnaires showed inconsistencies or if data were
missing, the concerned were contacted by a nutritionist and
asked for clarification. All questionnaires remained anon-
ymous, and persons other than the nutritionist entered all
the data in a blinded fashion.
Statistical analysis
Differences in categorical factors between patients and
controls were determined by using the x2 test. Differences
in continuous variables were computed by using the Mann–
Whitney U test (characteristics of patients and controls) and
Student’s t test (univariate nutrient comparison). To obtain
nutrient data that were not correlated to total energy intake,
the energy-adjusted values were calculated according to the
residual method.26 Nutrient data were categorised into tertiles
based on the data of controls, and multivariate logistic
regression was used to determine independent ORs for the
association between intake of nutrients and ALS, the lowest
tertile being the reference category. These three-level
variables were also entered into the model as continuous
variables to determine whether there was a linear trend. The
multivariate model always included the following possible
confounders: sex, age (at onset for patients, current age for
controls), level of education (low, middle, high), smoking
(never, ever, current) and (premorbid) BMI.
If nutrients were markedly associated with ALS and
biological interaction could be hypothesised, the interaction
between these nutrients was tested by entering both
nutrients and their product into the multivariate model.
We also carried out an exploratory analysis to test the
possible association between clinical features (age at onset
and duration of disease) and those nutrients that were
independently associated with the risk of developing ALS.
Cox regression analysis was used to determine the indepen-
dent association between the intake of nutrients and age at
onset of ALS adjusting for the above-mentioned confounders
and type of onset. The same procedure was used to determine
the independent association between intake of nutrients and
duration of disease, additionally adjusting for age at onset
and type of onset.
All tests were two-sided, and a p,0.05 was considered to
be significant.
RESULTS
Characteristics of patients and controls
Table 1 shows the characteristics of patients and controls,
including the main potential confounding factors for the
relationship between nutrient intake and ALS.
Rev 7.51n/W (Jan 20 2003)
Journal of Neurology, Neurosurgery, and Psychiatry jn83378 Module 1 10/4/06 10:28:17 Topics:
Table 1 Characteristics of patients with amyotrophic
lateral sclerosis (ALS) and controls
Patients with ALS
(n = 132)
Controls
(n = 220)
Age (years), median (range)* 58 (25–79) 59 (28–81)
Sex, n (%)
Male 89 (67) 136 (65)
Female 43 (33) 73 (35)
Site of onset, n (%)
Spinal 105 (79)
Bulbar 27 (21)
El Escorial category, n (%)
Possible 29 (22)
Probable 79 (60)
Definite 24 (18)
Education, n (%)
Low 46 (35) 64 (31)
Middle 44 (33) 62 (30)
High 42 (32) 82 (39)
Relationship with patient, n (%)
Friend 106 (51)
Direct family of partner 65 (31)
Neighbour 11 (5)
Partner 8 (4)
Direct family of patient 8 (4)
Therapist or care giver 6 (3)
Colleague 4 (2)
Smoking, n (%)
Never 42 (32) 60 (30)
Ever 61 (46) 101 (51)
Current 29 (22) 39 (20)
Premorbid or current BMI, median,
kg/m2 (range)`
25 (18–50) 25 (19–40)
Obese (.30) 9 (7) 11 (5)
Overweight (25–30) 60 (46) 89 (43)
Normal or underweight (,25) 63 (48) 108 (52)
BMI, body mass index.
*Age at onset of disease for patients and current age for controls.
For patients in the year before the onset of disease.
`For patients, premorbid BMI; for controls, current BMI; in some cases,
the sum of the data is not equivalent to the total of patients or controls, as
some values are missing.
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A representative sample of patients with ALS was obtained
with respect to sex, although a younger age at onset and a
relative predominance of patients with spinal onset in our
sample suggest some referral bias as compared with a recent
population-based study.27
Patients and controls were not markedly different with
regard to potential confounders (age, p=0.21; sex, p=0.66;
education, p=0.37; smoking, p=0.73; BMI, p=0.72). All
analyses were adjusted for age and other potential confound-
ing factors (gender, level of education, BMI and smoking).
Daily nutrient intake and risk of developing ALS
Table 2 compares the mean, energy-adjusted daily intake of
nutrients between patients and controls.
Premorbid total energy intake was similar in the two
groups, which is in accordance with similar premorbid BMI
levels (table 1). Univariate analysis of total cholesterol intake
showed a higher intake in patients with ALS, although this
difference did not reach significance. Intake of polyunsatu-
rated fatty acid (PUFA) and vitamin E was noticeably lower
in patients with ALS than in controls. Premorbid daily intake
of dietary supplements (mostly combinations of several
nutrients) was also assessed, but did not differ significantly
between patients and controls.
Figure 1 shows the adjusted ORs for the relationship
between energy-adjusted intake of nutrients and ALS.
Multivariate analysis showed that the inverse association of
intake of PUFAs and vitamin E with ALS was again highly
significant. The highest tertile of daily PUFA intake (.32 g)
was associated with a 60% lower risk of ALS compared with
the lowest tertile (,25 g). The second tertile of vitamin E
(18–22 mg) was associated with a 60% lower risk of ALS; the
highest tertile of vitamin E intake (.22 mg) was associated
with a 50% lower risk of ALS compared with the lowest tertile
(,18 mg). The association with cholesterol intake was not
significant (highest tertile compared with the lowest tertile
OR=1.6, 95% CI=0.9 to 2.7, p=0.11).
Interaction analysis showed that the ORs for vitamin E
were further reduced from 0.67 to 0.37 (p=0.02), and for
PUFA from 0.60 to 0.26 (p=0.005), with a significant
interaction term (p=0.03).
Flavonols, lycopene, vitamin B2 (not shown) and vitamin C
did not show any significant association. Analysis of
glutamate, calcium and phytoestrogens all yielded adjusted
p.0.73.
Daily nutrient intake and clinical features
No salient association between PUFA and vitamin E intake
and age at onset or duration of disease was found with
multivariate Cox regression analysis. PUFA and duration of
disease: hazard ratio (HR)=0.94, 95% CI=0.7 to 1.3,
p=0.72. PUFA and age at onset: HR=0.94, 95% CI=0.7
to 1.2, p=0.63. Vitamin E and duration of disease: HR=1.2,
95% CI=0.9 to 1.7, p=0.18. Vitamin E and age at onset:
HR=0.93, 95% CI=0.7 to 1.2, p=0.52.
DISCUSSION
We investigated the association between intake of nutrients
and the risk of developing ALS, as we hypothesised that daily
nutrient intake can modify observed pathological processes in
ALS, including oxidative stress, mitochondrial dysfunction,
apoptosis, inflammation and glutamate excitotoxicity. This
study showed that higher premorbid dietary intake of PUFAs
and vitamin E was associated with a 50–60% decreased risk
of developing ALS. These associations were independent of
possible confounding factors and total energy intake.
The finding that a higher intake of PUFAs appeared to
decrease the risk of developing ALS may be in accordance
with the results of studies in patients with other primarily
neurodegenerative disorders such as Alzheimer’s disease and
Parkinson’s disease.12 28 Omega 3 PUFAs—eicosapentanoic
acid, docosahexanoic acid and alpha-linolenic acid—in
particular, have been shown to protect against cardiovascular
disease and Alzheimer’s disease.29 In contrast, omega 6 fatty
acids—linoleic acid—have opposite mechanisms of action.29
Arachidonic acid—derived from linoleic acid and eicosapen-
tanoic acid—compete for the cyclooxygenase enzyme for
conversion into prostaglandins. The prostaglandins derived
from omega 6 are proinflammatory and those derived from
omega 3 are anti-inflammatory.29 Inflammation and upregu-
lation of cyclooxygenase have both been described in ALS.30
One previous study, however, found an association between a
higher intake of PUFAs and a higher risk of developing ALS.4
The fact that the current food-frequency questionnaire was
validated specifically for fat and cholesterol may partially
explain this discrepancy.15 Also, because neither study
differentiated between omega 3 and omega 6 PUFAs,
differences between an American and European study
population in consumption of specific foodstuffs that contain
predominantly omega 3 (fish, dark green leafy vegetables) or
omega 6 (cereals, whole-grain bread, baked goods, fried
foods) PUFAs may also have contributed to these discrepan-
cies.
Another possible mechanism of action of PUFAs is direct
neuroprotection through attenuation of glutamate excito-
toxicity.31 Omega 3 fatty acids—for example, alpha-linoleic
acid—have been shown to protect neurones from kainate-
induced cell death, probably through ion channels that are
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Table 2 Mean (SD) levels of premorbid daily nutrient intake in patients and controls
Patients with ALS patients
(n = 132) Controls (n = 220) p Value
Energy intake (MJ/day) 12.3 (4.0) 11.9 (4.3) 0.40
Total fat (g) 135.2 (27.6) 140.2 (30.2) 0.12
Saturated fat (g) 51.2 (10.5) 50.0 (8.6) 0.24
Monounsaturated fat (g) 49.8 (17.2) 52.5 (28.1) 0.33
Polyunsaturated fat (g) 25.5 (10.5) 29.3 (12.0) 0.003
Cholesterol (mg) 314 (75) 297 (91) 0.07
Flavonols (mg) 24.4 (19.5) 27.1 (19.1) 0.20
Lycopene (mg) 4.6 (3.5) 4.5 (3.6) 0.68
Glutamate (mg) 826 (382) 804 (347) 0.58
Vitamin C (mg) 133 (69) 145 (78) 0.16
Vitamin E (mg) 17.8 (7.1) 20.5 (9.2) 0.004
Riboflavin (mg) 2.0 (0.5) 2.0 (0.5) 0.78
Calcium (mg) 1223 (452) 1195 (383) 0.53
Phytoestrogens (mg) 0.34 (1.3) 0.89 (4.3) 0.15
Dietary supplements n (%) 43 (33) 78 (36) 0.58
Values are energy adjusted according to the residual method.
The risk of developing ALS 3
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also activated by riluzole—the only drug currently effective in
ALS.31 Furthermore, a protective effect of PUFA intake may
also suggest a link with cardiovascular disease, similar to
Alzheimer’s disease.32 Chronic hypoperfusion with hypoxia
could contribute to mitochondrial dysfunction and motor
neurone death in ALS. The recent finding that vascular
endothelial growth factor may be implicated in the process of
motor neurone degeneration in ALS33 either reaffirms a defect
Rev 7.51n/W (Jan 20 2003)
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Tertile
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p trend = 0.29
p trend = 0.54
p trend = 0.89
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Figure 1 Adjusted ORs for the relationship between amyotrophic lateral sclerosis and (A) the intake of fatty acids and cholesterol and (B) flavonoids,
lycopene, glutamate, vitamin C and vitamin E. The ORs were adjusted for sex, age (age at onset for patients), level of education (low, middle, high),
smoking (never, ever, current), body mass index (underweight, normal, overweight) and total energy intake according to the residual method; SATFA,
saturated fatty acids; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid.
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in neurotrophin biology or suggests a role for chronic
hypoxia.
The observed protective effect of vitamin E intake and the
risk of developing ALS is in contrast with two previous
studies that showed a lack of association.4 8 In a subsequent
large study, however, regular users of vitamin E supplements
had a 40–50% reduced risk of developing ALS.34 Also, the
observation that vitamin E delays clinical expression in the
mouse model of ALS35 and the known inhibitory effects of
vitamin E on lipid peroxidation36 support a role for vitamin E
in modifying the risk of developing ALS. 4-Hydroxynonenal,
itself a product of lipid peroxidation in vivo, has been shown
to be bound to the glutamate transporter in patients with
ALS,37 thus damaging the transporter and contributing to
glutamate excitotoxicity. The combined analysis, including
the interaction term, indicates that vitamin E and PUFAs
increase their separate protective effects. Vitamin E may act
directly to reduce the risk of ALS as a known inhibitor of lipid
peroxidation, but it could also act indirectly through
inhibition of peroxidation of nutritional PUFAs. As a result,
a higher level of PUFAs will be available biologically.
As male sex is an established risk factor and late menarche
and early menopause seem to occur in women with ALS,38
intake of phytoestrogens was investigated in this study. The
intake of phytoestrogens was found to be similar in patients
and controls.
Premorbid dietary intake of glutamate was previously
shown to be higher in patients with ALS,4 suggesting a
possible dietary contribution to glutamate excitotoxicity. This
study, however, did not show any sign of premorbid
increased glutamate intake. Differences in the food-fre-
quency questionnaires that were used probably contributed
to this discrepancy. Nevertheless, it is unlikely that dietary
intake levels of glutamate are sufficient to cause marked
changes in levels of glutamate in the brain and spinal cord,
because glutamate levels in the central nervous system are
tightly regulated at the blood–brain barrier.39 40
The limitations of this study are the possible influence of
overmatching of controls, recall bias and the non-population-
based design. Overmatching, however, leads to false-negative
findings, further emphasising the positive finding of this
study. The effect of recall bias will also be small because
patients were not informed about our hypotheses regarding
vitamin E or PUFAs, and these data were calculated from
general dietary questions. Importantly, this case–control
study took into account the possible influence of preclinical
disease in assessing dietary intake and adjusted for important
confounders, including total energy intake, according to the
residual method.26 A population-based case–control study is
presently being conducted to generate class I evidence.
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